Global PSMA-Targeted PET Imaging Agent Market Strategic Research Report

Scope of the Report

The global PSMA-Targeted PET Imaging Agent market size is predicted to grow from US$ 1,731 million in 2025 to US$ 2,839 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.

In 2025, the global production of PSMA‑targeted PET imaging agents reached 3,539,400 vials, with an average selling price of US$500 per vial. The global annual production capacity of PSMA‑targeted PET imaging agents was approximately 5 million vials, and the gross margin was about 30.4%. A PSMA‑targeted PET imaging agent is a radiopharmaceutical that utilizes prostate‑specific membrane antigen (PSMA) as a molecular target and is imaged via positron emission tomography (PET). Its core structure consists of two components: a targeting ligand (such as PSMA‑11, PSMA‑617, PSMA‑1007, or other small molecules or peptides) that specifically recognizes and binds to PSMA protein, and a positron‑emitting radionuclide (such as ⁶⁸Ga, ¹⁸F, etc.) attached to the ligand. After injection into the human body, the imaging agent selectively accumulates in prostate cancer lesions and metastatic sites, and PET scanning generates three‑dimensional images with high sensitivity and high resolution to reveal tumor distribution. It is mainly used for initial staging of prostate cancer, localization of lesions after biochemical recurrence, and guidance for individualized treatment decisions. The upstream of PSMA‑targeted PET imaging agents includes radionuclides (e.g., gallium‑68, fluorine‑18), PSMA‑targeting ligands (small molecules, peptides, or antibodies), and nanocarriers/chelating agents. The midstream consists of manufacturers of PSMA‑targeted PET imaging agents, and the downstream is primarily applied in nuclear medicine and molecular imaging, precision diagnosis of tumors, and radiopharmaceuticals and nuclear medicine.

Currently, the market for PSMA‑targeted PET imaging agents is experiencing sustained growth, driven fundamentally by the rising demand for precision medicine in prostate cancer and the deepening integration of molecular imaging with radiopharmaceutical technologies. Owing to their high affinity and specificity for the PSMA target, these imaging agents have gradually expanded their clinical utility from mainly detecting lesions in patients with biochemical recurrence to broader applications across the entire prostate cancer care continuum, including initial staging, treatment response assessment, and active surveillance, with their clinical acceptance and guideline recommendations notably strengthened. However, large‑scale market development still faces challenges such as cold‑chain logistics and just‑in‑time delivery pressures imposed by short radionuclide half‑lives, variations in multi‑site production quality control standards, and disparities across countries in regulatory approval, reimbursement policies, and radiation safety regulations. Meanwhile, technological advances are focusing on novel ligand design, expansion of radionuclide options (e.g., the shift from ⁶⁸Ga to ¹⁸F), and integrated development under the theranostics concept. These innovations are not only broadening the indications but also shifting the competitive landscape from product‑centric rivalry toward platform‑based and comprehensive service capabilities. Overall, the industry is moving steadily toward greater precision, standardization, and accessibility.

Key Questions Addressed in this Report

What is the 10-year outlook for the global PSMA-Targeted PET Imaging Agent market?

What factors are driving PSMA-Targeted PET Imaging Agent market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do PSMA-Targeted PET Imaging Agent market opportunities vary by end market size?

How does PSMA-Targeted PET Imaging Agent break out by Type, by Application?

This report presents a comprehensive overview of the global PSMA-Targeted PET Imaging Agent market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 68Ga
• 18F

Segment by Core Carrier Materials

• First Generation
• Second Generation

Segment by Mechanism of Action

• Active Targeting
• Passive Targeting

Segment by Application

• Nuclear Medicine and Molecular Imaging
• Precision Oncology Diagnostics
• Radiopharmaceuticals and Radiopharmaceuticals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global PSMA-Targeted PET Imaging Agent market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Nuclear Medicine and Molecular Imaging, Precision Oncology Diagnostics, Radiopharmaceuticals and Radiopharmaceuticals evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact